Evaluation of Gut Microbiome Profiles in Adults with Chemotherapy-induced Peripheral Neuropathy Receiving Rectal Ozone Therapy in the Randomized Trial OzoParQT
Led by Bernardino Clavo, MD, PhD · Updated on 2026-09-25
42
Participants Needed
1
Research Sites
12 weeks
Total Duration
AI-Summary
What This Trial Is About
Chemotherapy-induced peripheral neuropathy CIPN is a common and challenging side effect of chemotherapy that can reduce treatment effectiveness and lower patients quality of life. Effective treatments for CIPN are limited, and this study explores the possible benefits of rectal ozone therapy as well as the role of the gut microbiome in CIPN severity and treatment response. The study is an observational analysis linked to a randomized clinical trial called OzoParQT, focusing on adult patients with any tumor type experiencing CIPN-related numbness or tingling.
Participants receive standard care for their CIPN symptoms combined with 40 sessions of rectal insufflation of an O3O2 gas mixture over 16 weeks. One group receives ozone therapy with increasing O3 concentrations from 10 to 30 gmL, while the control group receives oxygen only placebo. The study aims to compare gut microbiome profiles between patients who improve symptomatically and those who do not, and between those receiving ozone therapy and placebo.
During the 16-week study period, participants provide stool samples for gut microbiome analysis and complete questionnaires assessing neuropathy severity, quality of life, anxiety, depression, and biochemical markers of oxidative stress and inflammation. Researchers measure changes in patient-reported numbness and tingling, neuropathy severity scales, toxicity grades, and quality of life scores from baseline to the end of therapy. The study also monitors biochemical markers and psychological status to better understand the relationship between gut microbiome composition and CIPN.
CONDITIONS
Brief Title
Gut Microbiome Profiles in Patients With Chemotherapy-induced Neuropathy in the RCT OzoParQT (NCT06706544).
Research Team
B
Bernardino Clavo, MD, PhD
F
Francisco Rodríguez-Esparragón, BSc, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Fundación Canaria Instituto de Investigación Sanitaria de Canarias
Collaborating Sponsor
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Adults aged 18 years or older
Received chemotherapy treatment for any tumor type
Clinical diagnosis of numbness or tingling due to chemotherapy-induced peripheral neuropathy with toxicity grade 2 or higher for at least 3 months
No neurotoxic chemotherapy in the last 3 months
Cancer is stable or in remission
Life expectancy of 6 months or more
Women of childbearing potential must have a negative pregnancy test and agree to use contraception during the study
Signed informed consent for both the OzoParQT trial and the gut microbiota study
You will not qualify if you...
Younger than 18 years old
Lactating, pregnant, suspected pregnancy, or women of childbearing potential not using adequate contraception
Neuropathy symptoms suspected to be caused by diabetes or compression
Severe psychiatric disorders
Unable to complete quality of life questionnaires
Creatinine levels more than 5 times the normal limit
Clinically unstable or requiring urgent interventions
Progressing cancer needing recent systemic treatment or maintenance with neurotoxic chemotherapy
Life expectancy less than 6 months
Known allergy to ozone, glucose 6 phosphate dehydrogenase deficiency, or hemochromatosis
Contraindications or inability to receive rectal ozone therapy or attend treatment regularly
Not meeting all inclusion criteria
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 16 weeks
Participants receive standard care plus 40 sessions of rectal insufflation therapy with either ozone or oxygen over 16 weeks to manage chemotherapy-induced peripheral neuropathy symptoms.
Multiple sessions over 16 weeks
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SCREENING
Number of Arms
2
Similar Trials
Functional Assessment of Patients with Chemotherapy-Induced Peripheral Neuropathy Compared to Controls
Study of Depo-Medrol Injection to the Psoas Muscle After Lateral Lumbar Interbody Fusion Surgery
Effects on Hip Muscle Weakness, Thigh Pain, and Numbness
Effectiveness of Closed-loop Spinal Cord Stimulation Therapy
for Pain Relief and Quality of Life in Adults with Chemotherapy Induced Peripheral Neuropathy
Evaluation of Gut Microbiome Profiles in Adults with Chemotherapy-induced Peripheral Neuropathy Receiving Rectal Ozone Therapy in the Randomized Trial OzoParQT
Evaluating Cryotherapy to Reduce Nerve Damage from Weekly Paclitaxel Chemotherapy in Female Breast Cancer Patients
Study of Nerve Recovery After Nitrous Oxide Abuse in Patients Aged 16 to 40
Evaluating Ozone Therapy Added to Usual Care for Numbness and Tingling from Chemotherapy-induced Peripheral Neuropathy A Randomized, Triple-Blind Clinical Trial
Comparing Sensory Outcomes, Chronic Pain, and Satisfaction in Cancer and Transgender Patients Undergoing Mastectomy and Reconstruction With or Without Nerve Reinnervation
Sensory Testing to Predict Response to Pain Treatments in Peripheral Neuropathy A Randomized Double-Blind Crossover Trial Comparing Pregabalin, Duloxetine, and Placebo
Study on Cold Salt and Unsalted Water Foot Baths to Prevent Nerve Damage from Chemotherapy in Women with Breast Cancer
Long-Term Effects of Ozone Treatment in Patients with Persistent Numbness and Tingling Secondary to Chemotherapy-Induced Peripheral Neuropathy. A Retrospective Study.
Bernardino Clavo, Delvys Rodríguez-Abreu, Saray Galván-Ruiz...